<DOC>
	<DOCNO>NCT01468155</DOCNO>
	<brief_summary>It hypothesize peri-ablation Dabigatran safe effective method peri-procedural anticoagulation Atrial Fibrillation ( AF ) ablation , result low rate peri-procedural bleeding thromboembolic complication .</brief_summary>
	<brief_title>DAPPAR AF Dabigatran Peri Procedural Anticoagulation During Radiofrequency Ablation Atrial Fibrillation</brief_title>
	<detailed_description>All patient initiate fix dose Dabigatran 150 mg BID least one month prior ablation procedure . If patient already warfarin therapy , warfarin stop minimum 2 day prior Dabigatran initiation , INR le 2 . Patients remain dose Dabigatran day ablation . On day prior ablation , patient take Dabigatran , take day ablation , sheath removal . For patient high-risk group bleeding , low dose Dabigatran may use , drug may stop advance procedure . For patient age great 80 year old , low dose Dabigatran ( 110 mg BID ) may use alternative . For patient impaired renal function , low dose may use , drug may stop early advance procedure per suggestion Appendix A. Post-ablation , Dabigatran start dose - either 150 mg 110 mg - ablation procedure . Dabigatran initiate 8 hour post sheath removal continue twice daily three month follow-up .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Patients age 18 great . Patients undergoing firsttime catheter ablation AF . Patients paroxysmal persistent AF . Paroxysmal AF define selfterminating episode le 7 day duration . Persistent AF define episode last longer 7 day duration episode require termination electrical chemical cardioversion . Patients symptomatic AF refractory least one antiarrhythmic medication . `` Symptomatic '' patient aware AF anytime within last 5 year prior enrollment . Symptoms may include , restrict , palpitation , shortness breath , chest pain , fatigue , leave ventricular dysfunction , symptom , combination . At least one episode AF must document ECG , Holter , loop recorder , telemetry , transtelephonic monitoring within 24 month entry trial . Patients must able willing provide write informed consent participate clinical trial . Patients AF felt secondary obvious reversible cause ( e.g . thyroid disease , postsurgical ) . Patients contraindication systemic anticoagulation heparin direct thrombin inhibitor . Patients severe renal impairment ( creatinine clearance &lt; 30 ml/min ) Patients leave atrial size &gt; /= 60 mm ( 2D echocardiography , parasternal long axis view ) . Patients may potentially pregnant effective method birth control plan get pregnant study . Patients mechanical heart valve . Patients undergo repeat catheter ablation AF . Patients hemorrhagic manifestation , bleed diathesis , patient impairment hemostasis . Lesions risk clinically significant bleed extensive cerebral infarction within last 6 month , active peptic ulcer disease recent bleeding . Concomitant treatment strong Pglycoprotein inhibitor , i.e . ketoconazole . Known hypersensitivity Dabigatran Dabigatran etexilate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>PVA</keyword>
	<keyword>peri procedural bleeding complication</keyword>
</DOC>